Verified Member
  • Content count

  • Joined

  • Last visited

  • Days Won


autigeremt last won the day on July 8 2016

autigeremt had the most liked content!

Community Reputation

415 Sterling

About autigeremt

  • Rank
    H2O is Life
  • Birthday 01/25/1972

Contact Methods

  • Website URL

Profile Information

  • Interests
    AU Sports and Education. Tournament Fishing and anything H2O related.
  • Location
    Auburn University (South Carolina Native)
  • Gender
  1. Damn! Gut shot brother. Godspeed and War Damn Eagle! We are praying for you.
  2. 8-1 in Montgomery v/s the turds. War Eagle!
  3. Pay attention, as I can’t say this seriously enough. Last week, the FDA took a drug off the market, and the reasons should send shivers of fear down the backs of consumers, investors, generic drug companies – and the FDA. The FDA announced last week that the 300mg generic version of Wellbutrin XL manufactured by Impax Laboratories IPXL +% and marketed by Teva Pharmaceuticals was being recalled because it did not work. And this wasn’t just a problem with one batch – this is a problem that has been going on with this particular drug for four or five years, and the FDA did everything it could to ignore it. The FDA apparently approved this drug – and others like it – without testing it. The FDA just assumed if one dosage strength the drug companies submitted for approval works, then the other higher dosages work fine also. With this generic, American consumers became the FDA’s guinea pigs to see if the FDA's assumption was right. It wasn't. Background In December 2006, the first generic versions of the popular anti-depressant Wellbutrin XL were approved by the FDA. The drug comes in two dosage strengths, 150 milligrams and 300mg. The 300mg dose is generally used for patients with more severe depression and anxiety and patients who don’t respond to the lower dose. The FDA approved generic versions of both dosage strengths from a few generic drug companies: Teva Pharmaceuticals (manufactured by Impax Laboratories and marketed by Teva Pharmaceuticals), Anchen, Actavis, Watson Pharmaceuticals WPI +% and Mylan MYL +0.08% Pharmaceuticals. Almost immediately, the FDA started receiving reports from patients that claimed the 300mg dose was being associated with side effects and reduced efficacy. The People’s Pharmacy, a well-known syndicated radio and newspaper columnist husband and wife team, notified the FDA that hundreds of patients had logged their own complaints of side effects with the then-recently approved generic version of Wellbutrin XL. The FDA brushed off the People’s Pharmacy and others that raised the issue, stating that they had faith that the drugs were equivalent and that perhaps the patients, who had mental disease, were more prone to perceived problems with a change in the medication than others. This was seen by many as essentially telling patients “it’s all in their head.” After several more years and public outcry, the FDA was forced to take action. What Action Did The FDA Take? Instead of doing its own study on the drug, the FDA asked the drug maker to conduct a study to determine whether the generic drug was equivalent to the brand. The FDA, in their recent press release, claims that Teva started the trial but later abandoned it because of slow patient enrollment. It was already 2010, several years after knowing there was a problem, the FDA was forced to do its own study. Continued on next page...
  4. Horsemanship lost this one for us. Ladies need to get better and ride for the National Title now.
  5. Speaking of changes in regulation. With just one sentence, Congress overturned OSHA’s rule that required employers to keep records of accidents and injuries for at least five years: “Congress disapproves the rule submitted by the Department of Labor relating to “Clarification of Employer’s Continuing Obligation to Make and Maintain an Accurate Record of Each Recordable Injury and Illness” (published at 81 Fed. Reg. 91792 (December 19, 2016)), and such rule shall have no force or effect.” The rule being overturned had required large employers in hazardous industries to keep their health and safety records for five years. Now, employers can destroy their Occupation Safety and Health Administration in as little as 6 months. The records are used by OSHA, employers, and workers to identify hazardous conditions and take corrective action to prevent future injuries and exposures. Without adequate data, it could be difficult to identify and fix hazards and incident patterns that could cause illnesses, severe injuries, or even deaths on the job. OSHA staffing is so low that it is only able to inspect workplaces once every 145 years (on average). Therefore, the agency relies on more than six months of records to recognize and fix problems. President Trump is expected to sign the bill.
  6. I'm familiar with Tier II reporting, EPCRA, etc. ADEM Air may go back to twice a year (we see them as well since we have a co-fired combustion incinerator on campus) but ADEM Waste Branch and others do not. A problem in Alabama is the fact that LEPC's do not do their prescribed job under law. Other groups are organized in ways that do not function as they are intended so I'm all about redundancy until something changes. As for ADEM there are some programs with one person (Medical waste for instance) who do not inspect. Water and Air do have a lot of turnover....most often because they are poorly funded, which goes back to my original issue with ADEM. They need more funding to keep good people. Once they get experience they leave and take that knowledge and training with them. Activist groups wouldn't need to file lawsuits if ADEM and the state did their jobs more effectively in my opinion.
  7. Rather have a stretch like this now than in May. Keep working, ladies. WDE!
  8. We need that extra bat that Snow was going to give us. Just keep getting better!
  9. Way to gut out a win on the road against thUGA. War Eagle! 9 in a row!
  10. My comment about illicit discharges was in reference to the funding squeeze. And you comments about ADEM responses to those discharges is no correct. Go look at the number of lawsuits on the books awaiting trial where ADEM isn't adhering to the Clean Water Act in regards to enforcement, fines and litigation. A lot of their issues stem directly from a lack of funding and the ability to keep good inspectors or hire the number needed to do the job. And ADEM doesn't inspect twice a year. They come by my Large Quantity Generator of Hazardous Waste facility once a year only. We manage over a 1,000 waste streams from nominal hazards to a pin drop kills hundreds. As for CSB, their findings from investigations provide information to insure a safer climate for the manufacture, delivery/transport and handing of hazardous chemicals which in turn provides a safer environment for the first responder community. Less means more (safety) in our line of work. Every layer of oversight dealing with these types of materials is a good thing.
  11. I believe they provide a valuable service. As a responder I like their role outside of EPA and OSHA because those agencies are not as effective in this arena in my opinion. PMSHA does a better job with Chemical Safety than the EPA and OSHA. Looking at the proposed budget by the WH it looks like they are ready to squeeze the EPA and cut funding to the states which will hurt ADEM even more. The Wild Wild West could be back when it comes to illicit discharges of hazardous materials.
  12. Here's their web doesn't take long to see the positive impact that they have.
  13. I think it's bad. I expect to see more safety failures in the future because of this. The U.S. Chemical Safety Board investigates all aspects of safety when it comes to chemical production, releases and impacts in this country. Trump is trying to make America "Polluted" Again!
  14. I believe Trump will try to dismantle the Clean Water Act as much as he possibly can.